TD Cowen lowered the firm’s price target on Alnylam to $260 from $265 and keeps an Outperform rating on the shares. The firm said its FDA CRL for Onpattro’s NDA for ATTR-CM was driven by APOLLO-B’s small effect size despite a positive AdComm and prior alignment with FDA on endpoints/SAP. While disappointing Onpattro/ATTR-CM did not meaningfully contribute to our thesis, TD Cowen said to investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALNY:
- Alnylam price target lowered to $233 from $266 at Citi
- Alnylam price target lowered to $175 from $210 at Morgan Stanley
- Alnylam announces FDA issues CRL for patisiran sNDA
- FDA PDUFA Date for Alnylam Patisiran (Onpattro) is October 8, 2023
- Alnylam initiated with Outperform on ‘robust’ pipeline at Raymond James